Blend CJC 1295 NO DAC 2MG with Ipamorelin 2MG

Blend CJC-1295 no DAC with Ipamorelin is a blend of two synthetic peptides — CJC-1295 and ipamorelin. CJC-1295 is a synthetic analog of the growth hormone-releasing hormone (GHRH). It stimulates growth hormone release by binding to the GHRH receptor. CJC-1295 is derived from another synthetic peptide known as sermorelin (GHRH 1-29).¹ It contains 30 amino acids and has a molecular weight of 3647.16 g/mol. CJC-1295 is available with or without an attached affinity complex (DAC), which was originally developed to help improve the peptide’s half-life. This formulation does not have DAC attached. Ipamorelin is a synthetic hexapeptide that stimulates growth hormone release via the growth hormone secretagogue receptor (GHS-R) found in the anterior pituitary gland.^2,3 It contains 6 amino acids and has a molecular weight of 711.39 g/mol. Ipamorelin mimics the function of ghrelin, despite having a different molecular structure. Together, the combination of CJC-1295 and ipamorelin is thought to enhance growth hormone release, because the two peptides stimulate it through binding to two different receptors. According to scientific research studies both peptides have shown to promote bone health and stimulate insulin release from the pancreas. Studies show that ipamorelin administration in rats is associated with a significant increase in bone mineral content compared to other growth hormone-releasing peptides.⁴ CJC-1295 supports bone health through its induction of insulin-like growth factor 1 (IGF-1), which is known to stimulate osteoblast activity for bone formation.⁵Ipamorelin stimulates IGF-1. Research studies indicate both peptides boost insulin production in pancreatic tissues through IGF-1 in animal models. In summary, CJC-1295 and ipamorelin affect similar pathways through growth hormone release and IGF-1 stimulation, and the use of both peptides together allows researchers to study their synergistic effects.

Blue Sky Peptide’s Blend CJC-1295 no DAC with Ipamorelin is available as a white lyophilized powder at a concentration of 4 mg/vial. CJC-1295 no DAC with Ipamorelin is intended for vitro scientific research.

References: 1. Alba M, Fintini D, Sagazio A, Lawrence B, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. m J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-1294. 2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-561. 3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-1416. 4. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-577. 5. Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol. 2003;41(3):228-234.